Development of a New Fusion-Enhanced Oncolytic Immunotherapy Platform Based on Herpes Simplex Virus Type 1
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-019-0682-1
Full Text
Open PDFAbstract
Available in full text
Date
August 10, 2019
Authors
Publisher
BMJ